{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["19(1)"],"submitter":["Marasini B"],"funding":["Government of Nepal, Ministry of Health and population, Department of Health Services, Epidemiology and Disease Control Division."],"pubmed_abstract":["<h4>Background</h4>Glucose-6-phosphate dehydrogenase (G6PD) deficiency is currently a threat to malaria elimination due to risk of primaquine-induced haemolysis in G6PD deficient individuals. The World Health Organization (WHO) recommends G6PD screening before providing primaquine as a radical treatment against vivax malaria. However, evidence regarding the prevalence and causing mutations of G6PD deficiency in Nepal is scarce.<h4>Methods</h4>A cross-sectional, population-based, prevalence study was carried out from May to October 2016 in 12 malaria-endemic districts of Nepal. The screening survey included 4067 participants whose G6PD status was determined by G6PD Care Start™ rapid diagnostic test and genotyping.<h4>Results</h4>The prevalence of G6PD deficiency at the national level was 3."],"journal":["Malaria journal"],"pagination":["287"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7425560"],"repository":["biostudies-literature"],"pubmed_title":["G6PD deficiency in malaria endemic areas of Nepal."],"pmcid":["PMC7425560"],"pubmed_authors":["Koirala D","Iama S","Khanal P","Ghimire P","Lal BK","Neupane S","Penpitchaporn P","Acharya S","Gornsawun G","Jha SN","Magar RG","Awasthi KR","Marasini B","Bhandari S","Bajracharya B","Chaudhary A","Koirala M","Mahato RK","Bhattarai RK","Bancone G","Acharya BP","Thapa S"],"additional_accession":[]},"is_claimable":false,"name":"G6PD deficiency in malaria endemic areas of Nepal.","description":"<h4>Background</h4>Glucose-6-phosphate dehydrogenase (G6PD) deficiency is currently a threat to malaria elimination due to risk of primaquine-induced haemolysis in G6PD deficient individuals. The World Health Organization (WHO) recommends G6PD screening before providing primaquine as a radical treatment against vivax malaria. However, evidence regarding the prevalence and causing mutations of G6PD deficiency in Nepal is scarce.<h4>Methods</h4>A cross-sectional, population-based, prevalence study was carried out from May to October 2016 in 12 malaria-endemic districts of Nepal. The screening survey included 4067 participants whose G6PD status was determined by G6PD Care Start™ rapid diagnostic test and genotyping.<h4>Results</h4>The prevalence of G6PD deficiency at the national level was 3.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2026-07-15T23:19:28.19Z","creation":"2025-04-07T11:42:46.662Z"},"accession":"S-EPMC7425560","cross_references":{"pubmed":["32787970"],"doi":["10.1186/s12936-020-03359-6"]}}